Market Closed -
Nasdaq
04:00:00 2024-04-15 pm EDT
5-day change
1st Jan Change
4.95
USD
-1.98%
-6.78%
-19.77%
OmniAb, Inc.(NasdaqGM:OABI) added to S&P TMI Index
December 19, 2022 at 12:00 am EST
OmniAb, Inc.(NasdaqGM:OABI) added to S&P TMI Index
OmniAb Insider Bought Shares Worth $1,167,750, According to a Recent SEC Filing
Mar. 25
MT
Sector Update: Health Care Stocks Gain Pre-Bell Thursday
Mar. 21
MT
OmniAb Swings to Q4 Loss, Revenue Declines
Mar. 20
MT
Earnings Flash (OABI) OMNIAB Posts Q4 Revenue $4.8M, vs. Street Est of $7.46M
Mar. 20
MT
Transcript : OmniAb, Inc., Q4 2023 Earnings Call, Mar 20, 2024
Mar. 20
OmniAb, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 20
CI
OmniAb, Inc.(NasdaqGM:OABI) added to NASDAQ Biotechnology Index
Dec. 18
CI
OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference
Dec. 14
CI
Omniab Insider Bought Shares Worth $1,010,000, According to a Recent SEC Filing
Dec. 13
MT
RBC Initiates OmniAb at Outperform With $6 Price Target, Says Stock Gives Exposure to Growth Potential of Monoclonal Antibody Therapies
Nov. 29
MT
Omniab Insider Bought Shares Worth $405,517, According to a Recent SEC Filing
Nov. 13
MT
Transcript : OmniAb, Inc. - Special Call
Nov. 09
OmniAb, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
Earnings Flash (OABI) OMNIAB Posts Q3 Revenue $5.5M, vs. Street Est of $10.3M
Nov. 09
MT
Omniab, Inc. Appoints Steve Love to Its Board of Directors and as Audit Committee Chair, Member of the Human Capital Management and Compensation Committee
Nov. 01
CI
A Collaborative Scientific Team Led by Researchers At the Applied Biomedical Science Institute, Scripps Research, Kansas State University, University of Louisville, Omniab, Inc., and Ligand Pharmaceuticals Discovers and Validates Potential New Class of Therapeutic Agent Based on the Unique Antigen Binding Regions of Cow Antibodies
23-09-20
CI
Insider Buy: Omniab
23-08-15
MT
OmniAb, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Transcript : OmniAb, Inc., Q2 2023 Earnings Call, Aug 10, 2023
23-08-10
Earnings Flash (OABI) OMNIAB Posts Q2 Revenue $6.9M, vs. Street Est of $11.9M
23-08-10
MT
Omniab Announces the Passing of Director Sunil Patel
23-08-07
CI
Hillstream Expands Collaboration With Minotaur, License Deal With OmniAb to Develop Cancer Treatments; Shares Rise
23-07-20
MT
OmniAb, Inc.(NasdaqGM:OABI) added to Russell 3000E Index
23-06-23
CI
OmniAb, Inc.(NasdaqGM:OABI) added to Russell Microcap Index
23-06-23
CI
OmniAb, Inc.(NasdaqGM:OABI) dropped from Russell 2500 Growth Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Companyâs OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
More about the company
Last Close Price
4.95
USD
Average target price
10
USD
Spread / Average Target
+102.02%
Consensus
1st Jan change
Capi.
-19.77% 580M -0.10% 42.07B +48.94% 42.16B +4.43% 39.77B -11.36% 26.68B +5.67% 24.68B -22.84% 18.68B -0.20% 12.11B +26.30% 11.99B +6.91% 11.06B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
OMNIAB, INC. 
